观点网讯:1月8日,上海复旦张江生物医药股份有限公司宣布认购中国银行结构性存款产品,涉及金额达人民币2亿元。复旦张江此次认购的中国银行人民币结构性存款产品,是一种保本浮动收益型产品,风险评级为低风险,期限为173天。该产品的预期年化收益率范围在0.85%至2.0712%之间,本金为人民币2亿元。产品挂钩指标为银行间电子交易系统(EBS)公布的国际黄金兑美元中间价,基准值为2025年1月8日北京时间...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.